Teachers Advisors LLC Purchased 6,120 Shares of Tocagen (NASDAQ:TOCA)

Teachers Advisors LLC Purchased 6,120 Shares of Tocagen (NASDAQ:TOCA)

Teachers Advisors LLC boosted its position in Tocagen (NASDAQ:TOCA) by 40.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,163 shares of the company’s stock after buying an additional 6,120 shares during the period. Teachers Advisors LLC owned approximately 0.11% of Tocagen worth $217,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. American International Group Inc. boosted its position in Tocagen by 112.9% in the fourth quarter. American International Group Inc. now owns 11,995 shares of the company’s stock valued at $123,000 after buying an additional 6,362 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in Tocagen in the fourth quarter valued at approximately $122,000. Geode Capital Management LLC boosted its position in Tocagen by 16.0% in the fourth quarter. Geode Capital Management LLC now owns 90,452 shares of the company’s stock valued at $927,000 after buying an additional 12,472 shares during the last quarter. California State Teachers Retirement System boosted its position in Tocagen by 103.4% in the fourth quarter. California State Teachers Retirement System now owns 28,070 shares of the company’s stock valued at $288,000 after buying an additional 14,270 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Tocagen by 2,075.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 15,099 shares of the company’s stock valued at $155,000 after buying an additional 14,405 shares during the last quarter. Hedge funds and other institutional investors own 32.55% of the company’s stock.

Tocagen stock opened at $8.97 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.23 and a current ratio of 5.23. Tocagen has a 12 month low of $8.60 and a 12 month high of $17.50. The company has a market capitalization of $182.40 million and a price-to-earnings ratio of -3.37.

Tocagen (NASDAQ:TOCA) last released its quarterly earnings data on Thursday, March 8th. The company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.02). Tocagen had a negative return on equity of 145.76% and a negative net margin of 94,948.78%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. sell-side analysts expect that Tocagen will post -2.3 earnings per share for the current year.

A number of equities research analysts recently commented on the company. ValuEngine upgraded Tocagen from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. BidaskClub upgraded Tocagen from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. Finally, Zacks Investment Research upgraded Tocagen from a “sell” rating to a “hold” rating in a research report on Thursday, January 11th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $21.50.

Tocagen Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Related posts

Leave a Comment